At a meeting of the NCI Board of Scientific Advisors March 29, NCI officials had good news to report:
Clifford Hudis was named CEO of the American Society of Clinical Oncology.
Brigham Doc’s NEJM Paper Decries Morcellation’s Demise—Did She Get Confidential Patient Information?
Update: The New England Journal of Medicine's subsequent response after this article is published is appended at the end.
Is Average Sales Price plus 6 percent the right amount to pay doctors under the Medicare Part B program?
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
Gilman's letter of resignation, dated May 8, 2012, concludes with a hard slam:
At its most recent meeting, in July 2015, the FDA Oncologic Drugs Advisory Committee voted…
President Barack Obama Feb. 8 unveiled his budget proposal for the 2017 fiscal year—a $4.1 trillion spending blueprint that is unlikely to be passed by a Republican-controlled Congress.
This series re-examines the concurrent controversies at the Cancer Prevention and Research Institute of Texas and MD Anderson Cancer Center. This examination is possible in part because of new insight provided by Alfred Gilman, a Nobel laureate who served as the first scientific director of the state institution that distributes $300 million a year. Gilman died on Dec. 23, 2015.
This series re-examines the concurrent controversies at the Cancer Prevention and Research Institute of Texas and MD Anderson Cancer Center. This examination is possible in part because of new insight provided by Alfred Gilman, the Nobel laureate who served as the first scientific director of the state institution that distributes $300 million a year. Gilman died on Dec. 23, 2015.
